Enzymotec (ENZY) Misses Q4 EPS by 2c; Issues Light GY15 EPS Outlook

Enzymotec (NASDAQ: ENZY) reported Q4 EPS of $0.06, $0.02 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $10.8 million versus the consensus estimate of $11.11 million.

Enzymotec sees FY2015 EPS of $0.21-$0.34, versus the consensus of $0.56. Enzymotec sees FY2015 revenue of $52-60 million, versus the consensus of $54.4 million.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Diana Shipping withdraws bid to acquire Genco Shipping